| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802457406019 | 245740601 | PEGINTRON PS.INJ.SOL 50MCG/0,5ML BT x 1πενα+1βελονα +2επιθεματα καθαρισμου +2επιθεματα καθαρισμου | 68.91 | 72.29 | 91.96 |
| 05/2018 | 2802457407016 | 245740701 | PEGINTRON PS.INJ.SOL 80MCG/0,5ML BTx1πενα+1βελονα +2επιθεματα καθαρισμου +2επιθεματα καθαρισμου | 110.11 | 115.50 | 142.02 |
| 05/2018 | 2802457408013 | 245740801 | PEGINTRON PS.INJ.SOL 100MCG/0,5ML BTx1πενα+1βελονα +2επιθεματα καθαρισμου +2επιθεματα καθαρισμου | 134.66 | 141.26 | 173.69 |
| 05/2018 | 2802457408020 | 245740802 | PEGINTRON PS.INJ.SOL 100MCG/0,5ML BTx4πενες+4βελονες +8επιθεματα καθαρισμου +8επιθεματα καθαρισμου | 541.04 | 549.17 | 628.68 |
| 05/2018 | 2802457409010 | 245740901 | PEGINTRON PS.INJ.SOL 120MCG/0,5ML BTx1 πενα+1 βελονα +2 επιθεματα καθαρισμου +2επιθεματα καθαρισμου | 162.98 | 170.97 | 206.60 |
| 05/2018 | 2802457409027 | 245740902 | PEGINTRON PS.INJ.SOL 120MCG/0,5ML BTx4πενες+4βελονες +8επιθεματα καθαρισμου +8επιθεματα καθαρισμου | 657.99 | 667.86 | 757.49 |
| 05/2018 | 2802457410016 | 245741001 | PEGINTRON PS.INJ.SOL 150MCG/0,5ML BTx1πενα+1βελονα +2επιθεματα καθαρισμου +2επιθεματα καθαρισμου | 205.89 | 208.98 | 248.10 |
| 05/2018 | 2802457410023 | 245741002 | PEGINTRON PS.INJ.SOL 150MCG/0,5ML BTx4πενες+4βελονες +8 επιθεματα καθαρισμου +8επιθεματα καθαρισμου | 833.46 | 845.97 | 950.53 |
For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
There is limited experience with overdosage. Postmarketing surveillance includes reports of patients receiving a single dose as great as 10 times the recommended dose. In general, the primary effects of an overdose are consistent with the effects seen with therapeutic doses of interferon alfa-2b. Hepatic enzyme abnormalities, renal failure, hemorrhage, and myocardial infarction have been reported with single administration overdoses and/or with longer durations of treatment than prescribed. Toxic effects after ingestion of interferon alfa-2b are not expected because interferons are poorly absorbed orally.
Absorption is high (greater than 80%) when administered intramuscularly or subcutaneously.
The elimination half-life following both intramuscular and subcutaneous injections was approximately 2 to 3 hours. The elimination half-life was approximately 2 hours following intravenous injection.
For the treatment of chronic hepatitis C in patients not previously treated with interferon alpha who have compensated liver disease and are at least 18 years of age.
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
Following a single subcutaneous dose of peginterferon alfa-2b, the mean absorption half-life (t&frac12; k<sub>a</sub>) was 4.6 hours.
The mean elimination half-life is approximately 40 hours (range 22 to 60 hours) in patients with HCV infection.
Renal elimination accounts for 30% of the clearance.
* Oral cl=22 mL/hr∙kg [patients with HCV infection]